Pharmasset Receives Notice of Allowance(ected. About Pharmasset Pharmasset...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Pharmasset Receives Notice of Allowance
Date:6/26/2008
ected.
About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing three product candidates. Clevudine,
for the treatment of chronic HBV infection, is enrolling Phase 3 clinical
trials for registration in North, Central and South America and Europe.
Clevudine is already approved for HBV in South Korea and marketed by
Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128,
an oral treatment for chronic HCV infection, is in a 4-week Phase 1
clinical trial in combination with Pegasys(R) plus Copegus(R) through a
strategic collaboration with Roche. Racivir, which is being developed for
the treatment of HIV in combination with other approved HIV drugs, has
completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.
Contact
Kurt Leutzinger
Chief Financial Officer
kurt.leutzinger@pharmasset.com
Office: +1 (609) 613-4110
Forward-Looking Statements
Pharmasset "Safe Harbor" Statement under the Private Securities
Litigation Reform Act of 1995: Statements in this press release regarding
our business that are not historical facts are "forward-looking statements"
that involve risks and uncertainties, including without limitation the risk
that the USPTO will withdraw the Notice of Allowance, adverse events could
cause the cessation or delay of any of the ongoing or planned clinical
trials and/or our development of our product candidates, the risk that we
cannot enroll enough patients for the Phase 3 registration clinical trial
for clevudine, the risk that our collaboration with
'/>"/>
| SOURCE Pharmasset, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine technology :
1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
(Date:11/25/2008)... Proteolix, Inc., a,leader in the...hat target,protein degradation pathways in cancer...ta from two ongoing Phase 2 clinical trials of car... the upcoming 50th Annual Meeting of the,American...first in a new class,of specific proteasome inhib...
(Date:11/25/2008)...re-FirstCall/ -- Pharmacyclics, Inc.,(Nasdaq: P...ed a Phase 1,clinical trial with PCI-27483, the c...tor VIIa inhibitor. The trial was conducted in six...ty and pharmacologic effect of,PCI-27483. A singl... dose,response in the International Normalized Ra...
(Date:11/25/2008)...Call/ -- CardioVascular,BioTherapeutics, Inc. (OT...as,dosed the first patient in North America (NA) ...reat patients with severe coronary heart disease. ...nary heart Disease) trial will include,four rando...pproximately 120,patients with severe coronary he...
(Date:11/24/2008)...e/ -- Domino,s Pizza (NYSE: DPZ ), the,recogniz...o raise dough for,the kids of St. Jude Children,s... and Giving campaign. Domino,s customers will have...urchase to benefit the children of St. Jude.,Dona...when ordering online at, www.dominos.com . The ca...
Breaking Medicine Technology:Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3MyHealthGate Inc Joins With LiveActive Chewy Granola Bars to Raise Digestive Health Awareness 27425 1MyHealthGate Inc Joins With LiveActive Chewy Granola Bars to Raise Digestive Health Awareness 27425 2Ohios Regulation of RU 486 Clear and Constitutional Should Be Upheld Argues AUL in Brief Filed Before Ohio Supreme Court 27423 1Ohios Regulation of RU 486 Clear and Constitutional Should Be Upheld Argues AUL in Brief Filed Before Ohio Supreme Court 27423 2CPF Fundraisers Bring in Landmark Half Million Dollars in Less Than Three Weeks 27421 1CPF Fundraisers Bring in Landmark Half Million Dollars in Less Than Three Weeks 27421 2CPF Fundraisers Bring in Landmark Half Million Dollars in Less Than Three Weeks 27421 3A Mindful Chocolate Meditation 27418 1A Mindful Chocolate Meditation 27418 2[1] Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology[0] Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483[0] CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease[1] Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign
...care System and,Worker Productivity, SAN DIEGO, Ju...iosciences, Inc. announced today that results from... primary and transient,insomnia were presented thi...ies (APSS) Annual Meeting. APSS highlights show th...uts a significant,strain on the Healthcare System ...
...BUSINESS WIRE)--Jun,13, 2007 - Amgen (NASDAQ:AMGN)...YSE:WYE), today announced the presentation of,addi... Enbrel(R),(etanercept) was maintained with long-t...le rheumatoid arthritis (JRA) who,completed up to ...e,disease of childhood that is sometimes difficult...
Other Medicine Technology:Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 2Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 3Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 4Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 5Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 2Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 3Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 4Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 5Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 6Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 7Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 8(Date:12/1/2008)...re/ -- In the face of one of the most,severe econ... Health Board of,Directors has approved an invest...d the Sutter Health Retirement Plan. Employee pens...ocks and bonds, have been among the biggest,casua...conservatively,invested, the Sutter Health Retire...
(Date:12/1/2008)...l/ - The Westaim Corporation today announced it ha...of NUCRYST Pharmaceuticals Corp. to consider a ret...ately US$15 million or US$0.80 per share. Westaim ...he value of its 74.5 per cent stake in NUCRYST. Un...,s Board of Directors has 20 days to call a meetin...
(Date:12/1/2008).../ -- ETHICON, Inc., a Johnson & Johnson compa...stiture of its Professional Wound Care business to...saction are not being disclosed. , , Under ...has acquired the Professional Wound Care product p...brands as PROMOGRAN Matrix Wound Dressing, TIELLE ...
(Date:12/1/2008)...swire/ -- Democratic National Committee Chairman H...mmemorating World AIDS Day on its 20th Anniversary...n/prnh/20080519/DNCLOGO ) , , "It,s been 20...e have made strides, much work remains to be done ...lobal strategy. We must focus not only on prevent...
Breaking Medicine News(10 mins):Health News:Sutter Health Invests Hundreds of Millions in Employee Pension 2Health News:The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 3[0] Sutter Health Invests Hundreds of Millions in Employee Pension[0] The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders[0] ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners[0] Statement of DNC Chairman Howard Dean on World AIDS Day
...alif., "In light of the recent news event where a ...is (XDR-TB) flew on multiple airline flights and ...r rapid identification of MTB and assessment of dr... the disease" said Dr. Nani Dattagupta, Chief Scie...
...N.Y., Over one hundred Long Island AARP members ga...slation before the end of the 2007 Legislative Ses...rugs more affordable and help assure that their ce...took their message directly to their legislators d...
...ta is interested in having a third child, but the ...s autistic condition public . Travolta has not com...s autistic. However, a magazine editor, who inter... the view that if Travolta doesnt shy away from ac...
...the Group of Eight industrialized nations plan to ...fighting the HIV/AIDS pandemic during their upcomi...t week, German Chancellor Angela Merkel's spokespe...n Wednesday, Reuters reports. Wilhelm said details...
Other Medicine News:Health News:Long Island Seniors Rally for Rx Affordable Prescription Drugs and Cell Phone Protections 2Health News:Travolta Maybe Reluctant to Publicaly Discuss About Sons Autism 2Health News:G8 Members To Announce Plans To Increase HIV/AIDS Spending at Summit 2For the quantitative in vitro determination of Sodium in serum and plasma.
Enzymatic assay for the quantitative in vitro determination of glycated protein (fructosamine) in human serum or plasma.
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |